31 July 2020 : Database Analysis
Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma
Dehua Zhang1ACD, Muchun Zhang2B, Qifu Zhang3DF, Zhiyi Zhao3BCF, Yong Nie1ADE*DOI: 10.12659/MSM.924543
Med Sci Monit 2020; 26:e924543
Table 2 Essential characteristics of the primary PRAD and normal solid tissue with RNA-seq data.
| Variables | Total samples (N=550) |
|---|---|
| Mean±SD | 61.01±6.82 |
| Median (range) | 61 (41–78) |
| Female | 0 (0.00%) |
| Male | 550 (100.00%) |
| T2a | 13 (2.36%) |
| T2b | 10 (1.82%) |
| T2c | 164 (29.82%) |
| T3a | 158 (28.72%) |
| T3b | 136 (24.73%) |
| T4 | 10 (1.82%) |
| Unknown | 7 (1.27%) |
| Normal solid tissue | 52 (9.46%) |
| N0 | 346 (62.91%) |
| N1 | 79 (14.36%) |
| Unknown | 73 (13.27%) |
| Normal solid tissue | 52 (9.46%) |
| Adenocarcinoma, NOS | 485 (88.18%) |
| Adenocarcinoma with mixed subtypes | 3 (0.54%) |
| Infiltrating duct carcinoma, NOS | 9 (1.64%) |
| Mucinous adenocarcinoma | 1 (0.18%) |
| Normal solid tissue | 52 (9.46%) |
| 6 | 45 (8.18%) |
| 7 | 248 (45.09%) |
| 8 | 64 (11.64%) |
| 9 | 137 (24.91%) |
| 10 | 4 (0.72%) |
| Normal solid tissue | 52 (9.46%) |
| Mean±SD | 1.86±3.39 |
| Median (range) | 0.10 (0.01–323.00) |
| Unknown | 84 (15.27%) |
| Normal solid tissue | 52 (9.46%) |
| Primary PRAD | 498 (90.55%) |
| Normal solid tissue | 52 (9.46%) |
| PRAD – prostate adenocarcinoma; SD – standard deviation; NOS – not otherwise specified; PSA – prostate-specific antigen. | |